drugset
drugset / Trial / NCT01654809

Safety and Immunogenicity Study of Split Influenza Virus Vaccine in Different Age Groups

NCT01654809 ↗

Phase 4 Completed 900 enrolled Beijing Center for Disease Control and Prevention
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to observe the adverse reaction ratio and hemagglutination inhibition (HI) antibody positive rate, Geometric mean titer (GMT) of three brands split influenza virus vaccine in different population.

Timeline

Start
2010-08
Primary completion
2011-02
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject domestic compared vaccine Vaccine 0.25 ml Intramuscular
Subject domestic compared vaccine Vaccine 0.5 ml Intramuscular
Subject evaluated vaccine Vaccine 0.25 ml Intramuscular
Subject evaluated vaccine Vaccine 0.5 ml Intramuscular
Subject imported compared vaccine Vaccine 0.25 ml Intramuscular
Subject imported compared vaccine Vaccine 0.5 ml Intramuscular

Indications

influenza